Akums Drugs and Pharmaceuticals Limited has been granted a patent for an invention entitled "Dual Release Gastro-Resistant Composition" for the term of 20 years from 19th November, 2022 in accordance with the provisions of the Patents Act, 1970.

The company has introduced an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment resistant gastroesophageal reflux disease (GERD) - one of the most common digestive disorders globally. GERD affects nearly 14% of the global population, with an estimated 784 million people living with the condition as of 2019, In India, recent meta-analyses estimate a pooled prevalence of 15.6%.

GERD occurs when stomach acid frequently flows back into the esophagus, causing heartburn and discomfort. PPIs such as Pantoprazole and Esomeprazole are highly effective in reducing stomach acid and healing acid-related damage. However, conventional PPIs may not last long enough, leading to nocturnal acid breakthrough and incomplete symptom relief.

To overcome this, Akums has developed Dual Release PPI tablets that release the medicine in two phases 50% in the duodenum and 50% in the ileum, and hence an extended absorption of drug, and hence extended duration of action. Therefore, dual release gastro resistant tablet of PPI has been designed to provide better heartburn free days (daytime or night time), long-lasting heartburn relief, improved compliance, and enhanced quality of life with just one tablet a day.

Using unique tablet-in-tablet technology, this formulation offers better stability, uniform drug release, and improved formulation attributes. This advanced, once-daily formulation has received DCGI approval and reinforces Akums' commitment to developing innovative and patient-friendly therapies for chronic acid-related disorders.